Insulin in Type 2 Diabetes – New Options are Transforming Management - Mainpro+


1 hr



# of Credits




Expiry Date


This 2-hour eCME program is an update lesson on the availability of new options in the management of Type 2 Diabetes. With the introduction of next-generation long-acting insulin analogues and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists (GLP-1 RA), people with diabetes have an increasing number of treatment options to achieve glycemic control. This program will update healthcare professionals on the management of T2DM with long-acting basal analogues and therapeutic intensification with combinations of basal insulin and GLP-1 RA

This Self-Learning program has been certified by the College of Family Physicians of Canada for up to 2 Mainpro+ Credits. Cert+ Program ID#: 189949


Ronald Goldenberg, MD, FRCPC, FACE

Gihane Zarifa, MD

Carl Fournier, MD

Daniel Ngui, BSc, PT, MD, FCFP

Upon successful completion of this program, the healthcare professional will be better able to:

  1. Determine when to initiate basal insulin therapy in type 2 diabetes
  2. Select a basal insulin and titrate the basal insulin dose according to Diabetes Canada 2018 guideline recommendations
  3. Discuss the differences between basal insulins
  4. Evaluate options for intensification for patients not reaching glycemic targets on basal insulin
  5. Explore the potential role of combination basal insulin and GLP-1 receptor agonist therapy and the role of fixed-ratio combinations

Related Courses